(object) array( 'id' => '8442002', 'url' => 'FR/thiomersal', 'image' => 'Vaccines with thiomersal.jpg;', 'title' => 'Thiomersal', 'tags' => array ( 0 => 'Thiomersal', 1 => 'Pharmaceutical', 2 => 'Vaccines', 3 => '', ), 'term' => 'Thiomersal', 'source_id' => 274263, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Vaccines', ), 'lastedit' => '20150721084102', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le thimérosal est un conservateur contenant du mercure qui est souvent utilisé dans les vaccins en raison de ses propriétés antiseptiques et antifongiques. L\'utilisation du thimérosal comme conservateur de vaccin a été controversée au cours des dernières années en raison du risque potentiellement accru de provoquer l\'autisme chez les enfants. Cependant, la dernière étude du CDC a toutefois montré qu\'aucun lien n\'avait été trouvé entre le thimérosal et l\'autisme.', 'usage_comment' => '', 'glossary' => '', 'width' => 485, 'height' => 385, '_version_' => 1507294573052821508, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'thiomersal', 'Definition' => 'Thimerosal is a mercury-based preservative that is often used in vaccines because of its antiseptic and antifungal properties. The use of thimerosal as a vaccine preservative has been controversial in recent years due to potentially increased risk of causing children\'s autism. However, the latest CDC study however showed no link found between thimerosal and autism', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => '', 'Sample Image' => 'Vaccines with thiomersal.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Vaccines', 'Domain' => 'Documentation; Marketing', 'Other Reference' => 'TIN', 'Creation User' => 'Williamb', 'Creation Date' => '2010/9/13', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'thiomersal', )

(object) array( 'id' => '10479588', 'url' => 'FR/Dermokil', 'image' => 'dermokillogo-1359898176.jpg;', 'title' => 'Dermokil', 'tags' => array ( 0 => 'Dermokil', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Dermokil', 'source_id' => 4925105, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083408', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Ezel Kozmetik a été fondée suite à une décision prise par l’homme d’affaire Ünal Karaca après avoir vu que l’on pouvait concevoir des produits cosmétiques à partir de sel de la mer Morte. Sur ce, il décida de produire des produits à base d\'argile qui sont utilisés depuis des siècles en Anatolie et plus récemment partout dans le monde et de promouvoir ses avantages en tant que produits cosmétiques. Les produits Dermokil (Produits Dermoclay) ont vu le jour à l’issue de 2 ans d’étude dans les laboratoires R&D et après les résultats positifs obtenus lors des essais effectués sur 2000 personnes. Les certificats d’enregistrement de marque et les rapports d’approbation établis par l’université Cumhuriyet, les matières premières et les produits ayant des rapports d’analyse microbiologique sont contrôlés par des dispositifs technologiques conformément aux normes nationales et internationales. Les analyses physiques, chimiques et microbiologiques des produits se réalisent d’une manière rapide et sûre à chaque étape de la production. L\'usine d\'Ezel Kozmetik composée d\'installations de production modernes a été établie à Sivas en 2006 et d\'une équipe de R&D composée d’ingénieurs chimistes experts en la matière, vise à devenir une marque leader dans le secteur de la cosmétique à travers ses machines de technologie avancée et son service logistique.', 'usage_comment' => '', 'glossary' => '', 'width' => 300, 'height' => 300, '_version_' => 1507928310837936128, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Dermokil', 'Definition' => 'Ezel Kozmetik was founded when Unal Karaca, the businessman, saw that the cosmetic products were made up of the salt of the Dead Sea and decided to produce the clay products which have been used in Anatolia for centuries and throughout the world during the recent years and to promote its benefits as a cosmetics. The Dermokil products (Dermoclay Products) appeared after testing on 2000 individuals and obtaining positive results and a two-year R&D study. Its brand registration certificates and the reports approved by Cumhuriyet University, the raw materials and products having microbiological analysis report are inspected by technological devices in national and international standards. In every stage of the production, the physical, chemical and microbiological analyses of the products are rapidly and reliably conducted. The factory of Ezel Kozmetik composed of the modern manufacturing plant established in Sivas in 2006 and an R&D team consisting of chemical engineers who are expert in their field aims to go ahead on the road to become a pioneer brand in the cosmetics sector through the high-tech machines and logistics services it provides.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Sample Image' => 'dermokillogo-1359898176.jpg;', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'dermokil', 'Creation Date' => '2013/2/5', 'Company' => '', 'Synonym' => '', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Dermokil', )

(object) array( 'id' => '7745840', 'url' => 'FR/experimental_treatment', 'image' => '', 'title' => 'Traitement expérimental', 'tags' => array ( 0 => 'Traitement expérimental', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Traitement expérimental', 'source_id' => 1259724, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084114', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le nouveau médicament ou thérapie testé dans l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821507, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'experimental treatment', 'Definition' => 'The new drug or therapy being tested in the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'experimental_treatment', )

(object) array( 'id' => '3898054', 'url' => 'FR/fixed-interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744252, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105905', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Programme de renforcement. Un renforçateur dépend de la première réponse après un intervalle de temps fixe depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330753, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'schedule of reinforcement. A reinforcer is contingent on the first response after a fixed interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed-interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed-interval_₁', )

(object) array( 'id' => '6228620', 'url' => 'FR/primary_outcome_measure', 'image' => '', 'title' => 'Critère de jugement principal', 'tags' => array ( 0 => 'Critère de jugement principal', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critère de jugement principal', 'source_id' => 4011188, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104701', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le critère de jugement défini dans le protocole qui est le plus important pour évaluer l\'effet d\'une intervention. La plupart des études cliniques ont un critère de jugement principal, mais certaines peuvent en avoir plusieurs.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081752334336, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The planned outcome measure in the protocol that is the most important for evaluating the effect of an intervention. Most clinical studies have one primary outcome measure, but some may have more than one.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'primary outcome measure', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'primary_outcome_measure', )

(object) array( 'id' => '3898055', 'url' => 'FR/fixed_interval_₁', 'image' => '', 'title' => 'Intervalle fixe', 'tags' => array ( 0 => 'Intervalle fixe', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle fixe', 'source_id' => 3744254, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105907', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un programme dans lequel une personne est renforcée par la première réponse après qu\'une période de temps fixe soit passée depuis le renforcement précédent. Ce programme induit généralement une pause après un renforçateur puis une augmentation progressive du rythme d\'émission des réponses jusqu\'à un niveau élevé au moment où le prochain renforçateur est reçu.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059392, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'A schedule in which a person is reinforced for the first response after a fixed period of time has passed since the previous reinforcement. This schedule usually causes people to pause after a reinforcer and then to gradually increase their response rate until they are working at a high rate at the moment they receive the next reinforcer.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'fixed interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'fixed_interval_₁', )

(object) array( 'id' => '6227765', 'url' => 'FR/inclusion_criteria', 'image' => '', 'title' => 'Critères d\'inclusion', 'tags' => array ( 0 => 'Critères d\'inclusion', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critères d\'inclusion', 'source_id' => 4010895, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105913', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les facteurs ou les raisons qui autorisent une personne à participer à une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107969, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The factors or reasons that allow a person to participate in a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'inclusion criteria', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'inclusion_criteria', )

(object) array( 'id' => '5178801', 'url' => 'FR/treatment-naive_₁', 'image' => '', 'title' => 'Patient naïf de traitement', 'tags' => array ( 0 => 'Patient naïf de traitement', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => 'Tylenol', 4 => '', ), 'term' => 'Patient naïf de traitement', 'source_id' => 3284753, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'product' => array ( 0 => 'Tylenol', ), 'lastedit' => '20150721112814', 'part_of_speech' => 'adjective', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '\'Patient naïf de traitement\' ou \'Patient naïf de médicaments\' se réfère à quelqu\'un n\'ayant encore jamais pris de traitement contre le VIH. Quelqu\'un qui prend déjà des médicaments est appelé \'patient déjà sous traitement\'.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507305079942676480, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'treatment-naive', 'Definition' => '‘Treatment-naive’ or ‘drug naive’ refers to someone who has never used HIV drugs. Someone who has used drugs before is called ‘treatment-experienced’.', 'Part of Speech' => 'adjective', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Product' => 'Tylenol', 'Creation User' => 'Chiara conte', 'Creation Date' => '2012/6/29', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'treatment-naive_₁', )

(object) array( 'id' => '3898053', 'url' => 'FR/variable_interval_₁', 'image' => '', 'title' => 'Intervalle variable', 'tags' => array ( 0 => 'Intervalle variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle variable', 'source_id' => 3744244, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105901', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '1) Un programme dans lequel une personne est renforcée par la première réponse après qu\'une période de temps variable soit passée depuis le renforcement précédent. Ce programme produit généralement un rythme de réponse uniforme. 2) Un programme de renforcement dans lequel une réponse est renforcée après qu\'une période de temps variable soit passée. Par exemple, dans un programme IV 30 secondes, l\'intervalle de temps varie entre chaque renforcement, mais l\'intervalle moyen de temps est de 30 secondes.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851728330752, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => '1) A schedule in which a person is reinforced for the first response after a varying period of time has passed since the previous reinforcement. This schedule usually causes a person to respond at a uniform rate. 2) A schedule of reinforcement in which one response is reinforced after a variable amount of time has passed. For example, on a VI 30-second schedule, the time to each reinforcement changes but the average time is 30 seconds.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'See Also' => 'interval schedules of reinforcement_₀', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable_interval_₁', )

(object) array( 'id' => '6229091', 'url' => 'FR/study_design', 'image' => '', 'title' => 'Plan d\'étude', 'tags' => array ( 0 => 'Plan d\'étude', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Plan d\'étude', 'source_id' => 4011443, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104709', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les méthodes d\'investigation utilisées dans l\'étude clinique. Pour les études interventionnelles, celles-ci incluent un objectif principal, un modèle d\'intervention, en insu ou en aveugle, et une affectation.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431489, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The investigative methods used in the clinical study. For interventional studies, these include primary purpose, intervention model , masking or blinding, and allocation.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'study design', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'study_design', )